Moderna Raises 2026 Revenue Growth Outlook Amidst Personalized Cancer Vaccine Program Success and New Flu Vaccine Approval
Trendline

Moderna Raises 2026 Revenue Growth Outlook Amidst Personalized Cancer Vaccine Program Success and New Flu Vaccine Approval

What's Happening? Moderna, a biotechnology company specializing in mRNA technology, has increased its 2026 revenue growth outlook to a range of 15% to 25%, up from an earlier forecast of up to 10%. This positive revision follows a significant third-quarter performance, where revenue rose 29% to $1.3
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.